Speakers at BIO Asia-Taiwan 2026 framed in vivo CAR T as a potential second phase of scalability for cell therapy, centering the discussion on delivery technologies. The session positioned in vivo approaches as a path toward improved durability and production practicality, but the emphasis stayed on how to route and control CAR T activity in living patients. The focus reflects how delivery remains the gating factor for broader translation.